Plantar Fasciitis Treatment Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 1.59 Billion |
| Market Size (2030) | USD 2.14 Billion |
| Growth Rate (2025 - 2030) | 6.97% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Plantar Fasciitis Treatment Market Analysis by Mordor Intelligence
The plantar fasciitis treatment market is valued at USD 1.59 billion in 2025 and is forecast to reach USD 2.14 billion in 2030, advancing at a 6.97% CAGR. Orthotic devices remain the backbone of care, but technology-enabled modalities such as extracorporeal shock-wave therapy (ESWT), AI-guided pressure-sensing insoles and ultrasonic fasciotomy are lifting the therapeutic ceiling. Demand growth aligns with the sharp rise in obesity and an aging global population—both proven risk amplifiers for plantar fascia degeneration. Reimbursement progress for outpatient embolization codes in North America, rising sports participation rates in Asia-Pacific and clinician preference for custom biomechanics correction are widening commercial opportunities. Meanwhile, fragmented competitive dynamics create room for consolidation, illustrated by Zimmer Biomet’s USD 5 billion purchase of Paragon 28, a specialist in foot and ankle products.
Key Report Takeaways
- By treatment type, orthotic devices led with 36.73% of plantar fasciitis market share in 2024; shockwave therapy is projected to expand at a 10.03% CAGR through 2030.
- By indication, acute presentations held 51.12% of the plantar fasciitis market share in 2024, whereas chronic cases are advancing at an 8.45% CAGR to 2030.
- By end user, hospitals accounted for 44.56% of the plantar fasciitis market size in 2024; ambulatory surgical centers are set to grow at an 8.12% CAGR over the same horizon.
- By geography, North America commanded 39.54% revenue share in 2024; Asia-Pacific is on track for a 9.06% CAGR, the fastest among all regions.
Global Plantar Fasciitis Treatment Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of plantar fasciitis fueled by obesity & aging population | +1.8% | North America, Europe | Long term (≥ 4 years) |
| Adoption of custom-made orthotic insoles & night splints | +1.2% | Developed markets worldwide | Medium term (2-4 years) |
| Rapid uptake of minimally-invasive ESWT & ultrasound-guided procedures | +1.5% | North America, Europe, expanding to APAC | Medium term (2-4 years) |
| AI-enabled pressure-sensing insoles enabling tele-rehab compliance | +0.9% | Developed markets first, scaling globally | Long term (≥ 4 years) |
| New outpatient reimbursement codes for embolization & ultrasonic fasciotomy | +0.7% | Primarily North America | Short term (≤ 2 years) |
| Sports-biomechanics data analytics driving preventive plantar products | +0.6% | Global sports-active populations | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Prevalence of Plantar Fasciitis Fueled by Obesity & Aging Population
Elevated BMI magnifies risk: adults with BMI ≥ 30 are five times more likely to develop plantar fasciitis than normal-weight peers.[1]Richard N. L., “Analysis of Data on the Prevalence and Pharmacologic Treatment of Plantar Fasciitis Pain,” National Center for Complementary and Integrative Health, nccih.nih.gov Prevalence peaks between ages 45-64, a cohort that is expanding quickly in most developed economies. Gender disparity is notable; women report plantar heel pain 2.5 times more often than men, prompting vendors to design gender-specific orthotics. Health systems now promote early orthotic use because 25% of untreated acute cases progress to daily chronic pain that requires costlier intervention.
Adoption of Custom-Made Orthotic Insoles & Night Splints
Three-dimensional printing with variable stiffness lets clinicians redistribute plantar pressure precisely along patient-specific arch geometry.[2]Liza S. Zaritsky, “Custom orthotic insoles with gradual variable stiffness using 3D printed spacer technique,” Taylor & Francis Online, tandfonline.com Trials show custom insoles outperform prefabricated versions on pain relief and recurrence rates, giving payers a clear cost-avoidance argument. Image-generative AI adds cosmetic customization that improves adherence, particularly among younger, fashion-conscious users. Night splints, once sidelined for discomfort, are returning as part of combination protocols that couple nocturnal stretching with daytime insole correction to maximize the healing window.
Rapid Uptake of Minimally-Invasive ESWT & Ultrasound-Guided Procedures
Controlled trials confirm that ESWT paired with targeted trigger-point therapy reduces pain more effectively than standalone waves.[3]Bo Wang, “Evaluation of the efficacy of trigger points combined with extracorporeal shock waves in the treatment of plantar fasciitis,” BMC Musculoskeletal Disorders, bmc.com The U.S. Department of Veterans Affairs now covers ESWT for chronic plantar fasciitis, a milestone likely to pressure commercial insurers toward broader acceptance. Ultrasound guidance boosts precision for fasciotomy and corticosteroid-sparing injections, while emerging ultrasonic fasciotomy tools remove diseased fascia through incisions <5 mm, lowering post-operative downtime.
AI-Enabled Pressure-Sensing Insoles Enabling Tele-Rehab Compliance
A 22-sensor solar-assisted insole from Ohio State University tracks gait cycles continuously and alerts clinicians when plantar pressures exceed healing thresholds. Machine-learning algorithms detect subtle biomechanical deviations months before pain escalates, letting therapists recalibrate orthotics remotely. Bluetooth connectivity and smartphone dashboards foster patient engagement, addressing a longstanding adherence gap in conservative care pathways.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost & patchy insurance coverage for advanced therapies | -1.4% | Global, sharpest in emerging markets | Medium term (2-4 years) |
| Counterfeit / low-grade orthotics undermining clinical outcomes | -0.8% | Emerging markets | Long term (≥ 4 years) |
| Shortage of certified podiatrists in emerging economies | -1.1% | APAC, MEA, Latin America | Long term (≥ 4 years) |
| Limited long-term evidence for regenerative injectables | -0.6% | Global premium segments | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
High Cost & Patchy Insurance Coverage for Advanced Therapies
Despite FDA clearance, many private insurers still label ESWT and ultrasonic ablation as investigational and refuse reimbursement anthem.com. Patients either absorb full procedural costs or revert to repetitive conservative therapy, delaying definitive care and inflating long-run expenditures. Emerging economies face even steeper barriers where out-of-pocket spending already tops 50% of total health expenditure.
Counterfeit / Low-Grade Orthotics Undermining Clinical Outcomes
\Online marketplaces often advertise “custom” insoles at a fraction of legitimate device prices but without clinical assessment or certified materials. Sub-standard arch support fails biomechanical correction and can worsen plantar overload, eroding patient trust in orthotic therapy and diluting brand reputation for bona fide manufacturers.
Segment Analysis
By Treatment Type: Orthotics Hold Leadership as Shockwave Accelerates
Orthotic devices contributed USD 0.59 billion and held 36.73% plantar fasciitis market share in 2024, underscoring the primacy of biomechanical realignment at the base of the care pyramid. The segment benefits from continuous material innovation—carbon-fiber composites, shape-memory polymers and breathable lattices—delivering lighter, more durable insoles without sacrificing corrective strength. Smart-insole variants are layering electronics atop traditional shells, turning static supports into data generators that inform tele-rehab pathways. Prefabricated inserts anchor entry-level demand, though custom CAD-CAM models grab higher margins and show lower 12-month recurrence.
The shockwave sub-segment is forecast to grow at 10.03% CAGR, fastest within the plantar fasciitis treatment market, aided by portable generators that allow outpatient delivery. Focused ESWT platforms now incorporate ultrasound imaging for real-time targeting, enhancing efficacy and curbing session counts. Regulatory clearances in Japan and Australia are drawing new device makers and regional distributors. Surgical interventions—endoscopic and ultrasonic fasciotomy—remain niche but vital for the 5-10% who fail conservative care. Regenerative therapies, including PRP and stem cells, sit at the innovative frontier yet await robust evidence and reimbursement traction.
Note: Segment shares of all individual segments available upon report purchase
By Indication: Acute Dominates but Chronic Expands Rapidly
Acute cases represented 51.12% of 2024 revenue, benefiting from guideline consensus around NSAIDs, stretching regimens and entry-level orthotic support. Early diagnosis campaigns by occupational health departments are trimming diagnostic delay, translating into quicker symptom resolution and lower downstream cost. Hospitals bundle acute care with gait-training programs, improving outcomes inside 12 weeks.
Chronic plantar fasciitis, however, is advancing at 8.45% CAGR and will command a growing slice of plantar fasciitis market size by 2030. The rise ties to lifestyle factors—prolonged standing professions, recreational endurance sports and delayed specialist referral. Chronic pathology unlocks demand for ESWT, ultrasound-guided injections and embolization, each commanding premium pricing. Transcatheter arterial embolization reports 82% pain reduction at 48 months follow-up, bolstering clinician confidence. Device firms position combination protocols, pairing shockwave priming with regenerative injectables, to tackle recalcitrant tissue degeneration.
Note: Segment shares of all individual segments available upon report purchase
By End User: Hospitals Retain Scale as Ambulatory Centers Surge
Hospitals generated 44.56% of the plantar fasciitis market size in 2024, leveraging integrated imaging, multidisciplinary staffing and reimbursement leverage. Complex surgeries—open or endoscopic fasciotomy—and comorbidity management occur predominantly in hospital theatres. Academic hospitals double as clinical-trial hubs, validating novel devices and biologics and shaping practice guidelines.
Ambulatory surgical centers (ASCs) are projected to grow at an 8.12% CAGR on the back of minimally invasive techniques and bundled episode-of-care pricing transparency. ESWT, ultrasound-guided corticosteroid injection and percutaneous ultrasonic fasciotomy fit well within ASC workflows that emphasize rapid turnover. Podiatry clinics serve as referral feeders, handling diagnostics and conservative care while channeling advanced interventions to ASCs. The direct-to-consumer home segment is nascent but expanding through smartphone-linked exercise modules and subscription orthotic replacements.
Geography Analysis
North America accounted for 39.54% of 2024 revenue. Mature insurance frameworks cover baseline orthotics and physical therapy, while recent code updates broaden access to outpatient embolization, anchoring the region’s technology adoption curve. The U.S. Food and Drug Administration’s 2025 approvals of pressure-mapped smart insoles and ultrasonic fasciotomy suites validate the innovation pipeline. Academic–industry collaborations feed continuous evidence generation, accelerating guideline acceptance across podiatry and orthopedics.
Asia-Pacific is set to log a 9.06% CAGR, the fastest in the plantar fasciitis treatment market. China’s Healthy China 2030 plan is scaling podiatry clinics inside tertiary hospitals, while India’s Ayushman Bharat insurance expansion improves affordability for outpatient therapies. Rapid urbanization increases sedentary office work and weekend sports participation, both driving plantar heel pain incidence. Device makers adapt with mid-tier ESWT units and subscription-priced 3D-printed insoles to match varied purchasing power.
Europe posts steady growth underpinned by universal healthcare and CE-mark streamlining for novel devices. Germany and the Nordic countries lead ESWT utilization per capita thanks to early payer adoption. Southern Europe reports rising use of electro-acupuncture protocols in chronic cases, blending traditional modalities with Western evidence standards. Regulatory harmonization across the EU eases cross-border supply for orthotic brands, while sports-medicine clinics tied to football clubs drive research into preventive footwear.
Latin America and the Middle East & Africa remain emerging opportunities. Brazil’s private insurance sector reimburses ESWT selectively, and medical tourism in Mexico offers bundled shock-wave packages to U.S. self-pay patients. Gulf Cooperation Council states invest in sports infrastructures ahead of global events, raising awareness of foot-ankle care and spurring demand for specialist clinics. However, podiatry workforce shortages and counterfeit orthotic inflows temper uptake until stronger regulatory enforcement materializes.
Competitive Landscape
The plantar fasciitis treatment market remains moderately fragmented, with the top five players controlling about 35% of global sales. Orthotic incumbents such as Hanger and Ottobock leverage long-standing clinician networks, yet face disruption from AI-driven custom-insole start-ups. Device majors Zimmer Biomet and Smith+Nephew are scaling dedicated foot-and-ankle portfolios through acquisitions and targeted R&D. Zimmer Biomet’s absorption of Paragon 28 extends its addressable products from joint replacement into high-growth forefoot reconstruction and plantar fasciitis implants.
Technology convergence is the new competitive yardstick. Firms integrating diagnostics, treatment and remote monitoring—often through cloud dashboards—enhance clinical efficacy and create data moats. Smart-insole pioneers partner with orthopedic giants for distribution reach, while cloud analytics monetize anonymized gait data for product design loops. Meanwhile, reimbursement lobbying remains a core capability; companies that secure Category I CPT codes or positive coverage determinations unlock scaled adoption and clinician loyalty.
Regional challengers pursue white-space strategies. Chinese ESWT manufacturers price devices 20-30% below Western averages, appealing to emerging-market clinics. Indian start-ups exploit the domestic 3D-printing ecosystem to deliver custom orthotics within 48 hours of foot scanning. European SMEs differentiate on sustainability, incorporating bio-based resins into insole fabrication to meet EU circular-economy directives. Consolidation is expected as multinational med-techs snap up niche innovators to reinforce pipeline breadth.
Plantar Fasciitis Treatment Industry Leaders
-
Scholl’s Wellness Co.
-
Ottobock
-
Algeo Limited
-
Bauerfeind
-
Superfeet Worldwide Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2025: ZenToes introduced next-generation compression socks across major U.S. retail chains, broadening its holistic foot-care offering.
- May 2025: Zimmer Biomet closed its USD 5 billion acquisition of Paragon 28, adding plantar fasciitis solutions to its expanding foot-and-ankle franchise.
- February 2025: Smith+Nephew launched a foot-and-ankle repair portfolio in Australia and New Zealand featuring adjustable tensioning anchors for Achilles reconstruction.
- February 2024: Hanger bought Fillauer to deepen orthotic manufacturing capabilities and bolster its North American clinic network.
Global Plantar Fasciitis Treatment Market Report Scope
As per the scope of the report, plantar fasciitis is the most common cause of heel pain. Plantar fasciitis occurs when the strong band of tissue that supports the arch of your foot becomes irritated and inflamed. The Plantar Fasciitis Treatment Market is segmented by Treatment Type (Pharmacological Treatment, Orthotic Devices, Shockwave Therapy, Surgery, and Other Treatment Types), End User (Hospitals, Ambulatory Surgical Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| Pharmacological Treatment | NSAIDs |
| Corticosteroid Injections | |
| Other Pharmaceuticals (botulinum toxin, analgesics) | |
| Orthotic Devices | Prefabricated Insoles |
| Custom-made Insoles | |
| Night Splints & Foot Braces | |
| Shockwave Therapy | Extracorporeal Shockwave Therapy (ESWT) |
| Focused Shockwave | |
| Radial Shockwave | |
| Surgery | Endoscopic Plantar Fasciotomy |
| Open Plantar Fasciotomy | |
| Ultrasonic Fasciotomy | |
| Regenerative & Novel Interventions | Platelet Rich Plasma (PRP) Injections |
| Stem-cell & Growth-factor Therapies | |
| Transcatheter Arterial Embolization | |
| Other Treatment Types |
| Acute |
| Chronic |
| Refractory and Others |
| Hospitals |
| Ambulatory Surgical Centers |
| Specialty Foot Clinics & Podiatry Centers |
| Home-care / Direct-to-Consumer |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Treatment Type | Pharmacological Treatment | NSAIDs |
| Corticosteroid Injections | ||
| Other Pharmaceuticals (botulinum toxin, analgesics) | ||
| Orthotic Devices | Prefabricated Insoles | |
| Custom-made Insoles | ||
| Night Splints & Foot Braces | ||
| Shockwave Therapy | Extracorporeal Shockwave Therapy (ESWT) | |
| Focused Shockwave | ||
| Radial Shockwave | ||
| Surgery | Endoscopic Plantar Fasciotomy | |
| Open Plantar Fasciotomy | ||
| Ultrasonic Fasciotomy | ||
| Regenerative & Novel Interventions | Platelet Rich Plasma (PRP) Injections | |
| Stem-cell & Growth-factor Therapies | ||
| Transcatheter Arterial Embolization | ||
| Other Treatment Types | ||
| By indication | Acute | |
| Chronic | ||
| Refractory and Others | ||
| By End User | Hospitals | |
| Ambulatory Surgical Centers | ||
| Specialty Foot Clinics & Podiatry Centers | ||
| Home-care / Direct-to-Consumer | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
1. What is the current value of the plantar fasciitis treatment market?
The market is worth USD 1.59 billion in 2025 and is projected to reach USD 2.14 billion by 2030 at a 6.97% CAGR.
2. Which treatment segment holds the largest share today?
Orthotic devices lead with 36.73% share in 2024 owing to widespread physician endorsement of custom biomechanical correction.
3. Why is shockwave therapy growing so quickly?
Clinical evidence and new coverage determinations are pushing ESWT to a 10.03% CAGR, the fastest among all modalities.
4. Which region will grow the fastest through 2030?
Asia-Pacific is forecast at a 9.06% CAGR, driven by expanding healthcare access, aging demographics and rising sports participation.
5. How are smart insoles changing plantar fasciitis management?
AI-enabled pressure-sensing insoles provide real-time gait analytics, improving treatment compliance and enabling tele-rehab pathways.
Page last updated on:
